Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X about a recent article by Daniele Marinelli et al., published in Cancer Treatment Reviews:
“Immunotherapy Rechallenge in NSCLC.
The largest meta-analysis to date (10 RCTs, n=3,081) showed that PD-(L)1 rechallenge provided modest OS (HR 0.91) and PFS (HR 0.89) benefits, with no ORR improvement.
No benefit was observed in primary resistance, while patients with acquired resistance appeared more likely to benefit (OS HR 0.86).
Resistance phenotype matters.”
Title: PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes
Authors: Daniele Marinelli, Fabrizio Citarella, Andrea Torchia, Sagal Pannu, Ayesha Aijaz, Luisana Sisco, Marco Russano, Yu Fujiwara, Kazuki Takada, Amin Nassar, Giuseppe Luigi Banna, Biagio Ricciuti, Leonardo Brunetti, Valentina Santo, Antonio Passaro, Stephanie Sawo, Molly Lip, Alfredo Addeo, Roberto Ferrara, Massimo Di Maio, Giannis Mountzios, Daniele Santini, Marcello Maugeri-Saccà, Bruno Vincenzi, Fabian Acker, Karen Reckamp, Federico Cappuzzo, Abdul Naqash, Alessio Cortellini
Read the Full Article on Cancer Treatment Reviews.
More posts featuring Diego A. Díaz-García.
